The presence of serum antibodies to the diol-epoxide DNA adducts of representative polycyclic aromatic hydrocarbons (PAH), chrysene, benzlalanthracene and benzoialpyrene, was determined by ELISA using serum samples obtained from normal healthy individuals. Antibodies that reacted against PAH adducted-DNA, but not against PAH-adducted protein, were found in the serum of -40% of the test individuals. Specificity analysis of the antibodies demonstrated that serological cross-reactions between the benzoialpyrene and the chrysene diol-epoxide adducts were present. Similar cross-reactivity between the benzialanthracene and the chrysene adducts was observed. Sera containing antibodies that were apparently specific for each of the three PAH-DNA adducts were also identified. The presence of antibodies to PAH-DNA adducts indicates both past exposure to these carcinogenic PAH and their metabolic activation to the DNA damaging metabolites. These antibodies may prove to be useful in both retrospective and prospective epidemiological studies of various diseases associated with PAH exposure.
Introduction
Polycyclic aromatic hydrocarbons (PAH)1 are a group of compounds that are present in the environment as the result ofthe combustion of organic matter. The sources and the levels of environmental contamination for many of these compounds have been determined (1) . Human exposure to complex mixtures of PAH occurs primarily through three routes: (i) the respiratory tract through the smoking of tobacco products (2, 3) and the inhalation ofpolluted air (5, 6) , (ii) the gastrointesti-nal tract through the ingestion ofcontaminated drinking water (4) and broiled, smoked, or otherwise processed foods (7) , and (ifi) skin contact, which usually occurs from occupational exposure (8) .
Many PAH have been recognized as common environmental pollutants and as potent carcinogens; benzo[alpyrene (BP) has been studied most extensively and is considered as the prototype compound. BP can be activated metabolically to the ultimate-carcinogen, 7A, 8a-dihydroxy-9alOa-epoxy-7, 8, 9, 10-tetrahydrobenzo[a]pyrene (BPDE). The activation of BP occurs through a multistep process that includes: (i) oxidation across aromatic double bonds by the action. ofthe mammalian cytochrome P450 enzyme system that results in the formation of simple epoxides, (ii) the formation of dihydrodiols by the action of epoxide hydrolases, and (iii) a second round of cytochrome P450 mediated oxidation at the site of olefinic double bonds to form the reactive diol-epoxides. The activated diol-epoxide binds primarily to the exocyclic amino groups of deoxyguanine in a covalent manner to form DNA adducts (9-1 1). The BPDE-DNA form is the major adduct that is detected in human tissues following experimental B[a]P exposure in vitro (12, 13) and in the DNA of peripheral blood lymphocytes (14, 15) and lung tissues (16) obtained from persons exposed environmentally to high levels of BP. The observations made concerning the metabolic activation and the formation ofadducts using Bla]P are considered to be representative for PAH as a class of chemical carcinogens (17) . We reported recently that the occupational exposure of coke oven workers to BP led not only to the formation of BPDE-DNA adducts, as was expected, but also to the production of antibodies that reacted with an epitope(s) on BPDE-DNA adducts (15) . The levels of BP to which coke oven workers are exposed are known to be very high, much greater than those found in the normal environment (6) , and as such the presence of BPDE-DNA adducts and/or antibodies to these adducts most likely reflects exposure to BP.
The detection of specific antibodies to adducts may serve as an indicator of environmental exposure ofhurmans to BP as well as other common PAH. To test this hypothesis and to characterize further the immune response against PAH adducts we assayed the sera from 99 healthy individuals who were exposed to average urban environmental levels of PAH. The purpose of this study was to determine if persons from urban environments with typical PAH exposure profiles responded immunologically to PAH-DNA adducts in a manner similar to that of the occupationally exposed coke oven workers. Data obtained from the characterization ofthis population can then be used as a baseline for the development of both retrospective and prospective environmental epidemiological studies involving PAH exposure ofhumans. The results of these studies are provided in this report. anol/tetrahydrofuran solution at a concentration of 1 mg/ml and mixed with 2 ml of the globin solution (50 mg/ml in PBS). Adducted globin was precipitated and recovered by multiple extractions with organic solvents as described for the preparation of PAH-DNA adducts. The precipitated globin was dissolved in PBS (22) . The amount of (3H]BPDE adducted to the globin was determined to be 16.9 pM BPDE/gg of globin by beta scintilation counting. This is a modification level of0.4-0.6% by weight, which was only slightly less than that which was achieved in the formation of DNA-adducts. Similar globin adducts could not be produced using the BADE or the ChDE because these compounds are not currently available in radioactively labeled forms and as such, modification levels could not were incubated for 60 min with the antigen containing wells and then washed five times with PBS. The binding of human immunoglobulin was then detected using the biotinylated goat anti-human immunoglobulin reagents and the avidin-biotin horseradish-peroxidase system (ABC Vectastain, Vector Laboratories, Burlingame, CA) as described by the manufacturer. The enzyme reaction was developed by the addition of 100 ,l ofthe substrate solution (0.05 M citrate buffer, pH 4.0; 1 mg/ml ortho-phenylenediamine plus 0.5 ul/ml of 30% H202 to each of the wells. The enzymatic reaction was stopped after a 20-min room temperature incubation by the addition of50 ul of2.0 M H2SO4. Plates were read using an automatic ELISA reader (Dynatech Laboratories, Alexandria, VA) and the absorbance at 490 nm was recorded. An anti-human immunoglobulin reagent that reacted with all isotypes of serum immunoglobulins was used. Each ELISA included the testing of a serum sample on modified and nonmodified DNA as well as on wells without any type of bound PAH-DNA (15) .
Antibody reactions to each of the DNA-adducts were scored as positive when the mean absorbance value of triplicate test wells was significantly greater than that observed in triplicate control wells containing nonmodified-DNA as the test antigen. Significant ELISA absorbance levels were established by adding two standard deviations to the control absorbance values. Antibody titers were determined as the highest dilution of serum for which significant ELISA absorbance levels were obtained.
Antigen-competition ELISA. Selected sehum samples that were found to contain antibodies that reacted against the PAH-DNA adducts were tested further using a competitive ELISA. In this assay the binding of antibodies to the solid-phase antigen was competed by the preincubation of the test serum with different test antigens before testing in the direct binding ELISA. Serum samples were diluted to a point at which binding was 80-90% maximal. The diluted serum samples were then mixed with varying amounts of modified or nonmodified DNA (400, 200, and 100 ng/ml) and incubated at room temperature for 60 min. These serum/PAH-DNA mixtures were then tested as described for the direct binding ELISA against both the modified and nonmodified DNA. The results are expressed as "percent inhibition"; which was determined by using the levels of antibody binding of each diluted serum sample without any competing antigens as the level of maximal binding and the background antibody binding ofeach sample as the level of minimal antibody binding (15) . The formula for determining this is as follows: (MAX -BKGD) -(TEST -BKGD)/(MAX -BKGD) X 100, where MAX, the ELISA absorbance value of triplicate test wells which was observed using the monoclonal antibodies without any competing antigens; TEST, the ELISA absorbance value oftriplicate test wells which was observed using monoclonal antibodies after incubation with competing antigens; BKGD, the ELISA absorbance value of triplicate test wells which was observed using no antigens on the solid phase, a measure of the background binding of the monoclonal antibodies to the polyvinylchloride surface of the ELISA test plates.
Competition binding was done using BPDE-, BADE-, ChDE-DNA, and control-DNA as both competing antigens and as solidphase test antigens in all combinations.
Competition binding was also assayed using soluble, nonmetabolized BP, BA and chrysene as the competing antigens. Crystalized BP, BA and chrysene (Aldrich Chemical Co., Milwaukee, WI) were dissolved in dimethyl sulfoxide (Sigma Chemical Co.) and then diluted in PBS to a concentration of I mg/ml PAH plus 10% (vol/vol) dimethyl sulfoxide in PBS and stored at -650C. This solution was diluted further as required using the 10% dimethyl sulfoxide-PBS solution. The antigen competition assays were run as described for the PAH-DNA adducts using the soluble PAH at concentrations of 400, 200, and 100 ng/ml. ELISA using BPDE-globin. The BPDE-globin and control-globin were attached to the wells of polyvinylchloride test plates by an overnight room temperature incubation of 200 ng/well total protein in 25
Ml of 0.06 M bicarbonate buffer, pH 9.6. The direct binding ELISA using globin was run exactly as described for the PAH-DNA adducts. The antigen competition ELISA was also run as described for the PAH-DNA adducts using BPDE-and control-globin at concentration of 4, 2, and 1 gg/ml as the competing antigens in the fluid phase.
The reasons for running the two forms of the ELISA, direct antibody binding and antigen competition, are as follows: (a) the results from the different forms of the ELISA were interpreted together to determine which PAH-DNA preparations share serologically defined epitopes; (b) the results from the different forms of the ELISA allowed us to compare the DNA and globin adducts to determine the immunological relatedness of these compounds; (c) the results from the different forms of the ELISA allowed us to identify those antibodies which recognized epitopes on PAH-DNA adduct preparations in the fluid phase and in the solid phase; an important consideration since attachment of antigens to the polyvinylchloride solid phase may distort the normal tertiary structure of the PAH-DNA adducts; (d) the results of the different forms of the ELISA allowed us the opportunity to partially quantitate the antibody binding with respect to the preference of serum antibodies for a particular PAH-DNA adduct.
Statistical analysis. Basic statistical analysis were done using the SAS program package (SAS Institute, Inc., Cary, NC); specific programs are identified as they are referenced in the next section. Epidemiologic organization of this study and subsequent analysis were done as described (23, 24 The presence of antibodies in a single serum that reacted against the three different PAH-DNA adducts was a common feature. Sera from 27 individuals reacted against all three types of the PAH-DNA adducts at one or more of the serum dilutions tested. These complex sera exhibited antibody binding curves similar to that shown for serum F8204 (Fig. 2 A) , in which the three different adduct preparations were recognized similarly, based on ELISA absorbance values and serum titrations. Four sera reacted in a preferential manner against two forms of the PAH-DNA adducts producing antibody binding patterns similar to those shown for serum F8066 (Fig. 2 B) with higher levels of antibody binding for BPDE-DNA and ChDE-DNA than for BADE-DNA, and serum F8268 which had antibodies only to BPDE-DNA and BADE-DNA (Fig. 2  C) . 12 sera reacted significantly against only a single PAH-DNA adduct as shown for the sera F820 1, F750 1, and F7435, which bound to ChDE-DNA, BPDE-DNA, and BADE-DNA, respectively (Fig. 2, D-F) .
The presence of antibodies to more than a single adduct in individual sera appeared to be more common than the presence of antibodies to only a single adduct. We analyzed these serological data using a 2 X 2 X 2 chi-squared contigency table with four degrees of freedom, using the CATMOD program (SAS Institute, Inc.); serological reactions were scored simply as either positive or negative with respect to each adduct. The distribution of the serological reactions against the three test adducts is shown in Fig. 3 along with the numbers of positive reactions expected assuming that antibody reactions were independent of each other. This analysis demonstrates that sera with antibodies against all three adduct types occurred much more frequently than was expected. Similarly, sera which were totally negative, in terms of antibodies to all of the adducts used, were identified much more frequently. This distribution of the data is significantly different than would be expected for independent antibody reactions against each of the adducts (P < 0.001).
The identification of sera with antibody reactivity against a single type of PAH-DNA adduct was a rare occurrence, however, their identification suggested that each of these adducts may possess at least one immunologically unique epitope. The presence of antibodies to more than a single type of PAH-DNA adduct in a serum was common and is also of interest in immunological terms. These complex binding patterns could be caused by the presence within a single serum of several specific antibodies against each of the different PAH-DNA adducts or these reactions may be due to the binding of antibodies that recognized a shared or cross-reactive epitope present on more than one ofthe chemical forms of PAH-DNA adducts. The antibody specificities of selected sera were therefore defined more rigorously using an antigen competition ELISA, an assay in which sera were preincubated with the different PAH-DNA adducts before being tested by ELISA to determine if antibodies with certain specificities can be inhibited. The results of these assays demonstrated that many ofthe complex sera did contain antibodies that were cross-reactive (Fig. 4) . Analysis of one of these sera, F8066, demonstrated that BPDE-DNA was capable of inhibiting the binding of serum antibodies to both BPDE-DNA (Fig. 4 A) and ChDE-DNA (Fig. 4 B) . The reverse situation was not true, ChDE-DNA did not inhibit the antibody binding to BPDE-DNA (Fig. 4 A) . However, BADE-DNA was also used successfully to partially inhibit antibodies from binding to ChDE-DNA (Fig.  4 B) thus documenting some degree of serological between these two different adducts. Cross-reactivity between BPDE-DNA and BADE-DNA could not be similarly demonstrated by antigen competition ELISA (Fig. 4, A and C) . Similar results were obtained using five other complex sera (data not shown). These data suggested that two different cross-reactive epitopes are present on the different PAH-DNA adducts used in this study, one on BPDE-DNA and one on BADE-DNA, each of which is present on the ChDE-DNA.
The ability of ChDE-DNA and BPDE-DNA to inhibit an-INHIBITING ANTIGEN CONCENTRATION (ng/ml) Figure 3 . Observed distribution of antibody reactions for 99 sera against the three test adducts (given as BP, BA, and CR for BPDE-DNA, BADE-DNA, and ChDE-DNA, respectively). The percentages of the total-panel identified with each adduct combination specificity are given in numerical fashion; the values in the parentheses represent the percentages of expected sera with each particular adduct combination specificity assuming that the presence of antibodies in all sera to each of the adducts is an ipdependent event.
tibodies in serum F8066 from binding to BADE-DNA could not be established accurately. The antibodies to BADE-DNA in this serum appeared to represent only a minor portion ofthe total PAH-DNA specific antibodies present and our inability to assess their function in the antigen competition ELISA was probably limited by this feature. However, serum F7435, which reacted with only a single chemical form of the PAH-DNA adducts (BADE-DNA specific) (Fig. 2 F) , was inhibited by only BADE-DNA (Fig. 4 C) ; BPDE-DNA and ChDE-DNA failed to compete for antibody binding. The analysis of this serum demonstrates the BADE-DNA can serve as an antigen and that it possesses an immunologicaly unique epitope. Similar analyses were done with the other sera that reacted against only a single adduct. The titers of many ofthese were to low to be informative however, inhibition of two BPDE-DNA specific sera was accomplished with only BPDE-DNA, inhibition of antibody binding by ChDE-DNA and BADE-DNA was not observed (data not shown). These data demonstrate that BPDE-DNA also possesses an epitope unique to this adduct, similar to the data for BADE-DNA serum F7435 (Fig. 4 C) . Similar data for ChDE-DNA was not obtained inspite of the apparent presence of ChDE-DNA specific sera, such as F8201 (Fig. 2 D) . This probably represents a combination ofa lack of sensitivity in our ELISA system and low titered ChDE-DNA specific sera.
Analysis of the direct antibody binding ELISA data in conjunction with the antigen competition ELISA data demonstrated both the presence of antibodies specific for each of the PAH-DNA adducts used, and therefore suggests the presence of epitopes unique to at least two of the PAH tested, and the presence of antibodies that cross-react with the different adducts, suggesting the presence of shared epitopes. These data also demonstrated agreement between the direct binding and the antigen competition forms of the ELISA thus alleviating our concerns that the attachment of PAH-DNA adduct preparations to the polyvinylchloride assay plates might alter the antigenic structure of the adducts. Antibodies that bound to PAH-DNA adducts were never inhibited by nonmodified DNA demonstrating that the specificities of the serum antibodies were produced by alterations in the DNA resulting from the presence of an adduct.
Selected sera were assayed further to characterize the specificities of the antibodies to PAH. Antigen competition ELISA using the parent hydrocarbons (B[a]P, B[a]A and chrysene) as the competing antigens established that antibodies which bound to the BPDE-DNA, BADE-DNA, or the ChDE-DNA adducts were not inhibited by these simple chemical moieties even at concentrations 100 times greater than those present as PAH-DNA adducts (data not shown). The possibility that the serum antibodies could bind to PAH conjugated to protein was investigated using BPDE-globin and nonmodified-globin as the test antigens. Antibody binding to the BPDE-globin was not detected using either the direct binding ELISA or the antigen competition ELISA (Fig. 5) . These data demonstrated that the serum antibodies are specific for PAH-DNA adducts. We believe this to indicate that the PAH-DNA adducts were probably the immunogens against which the antibodies were produced, since serum antibody reactivity was not detected against PAH-protein complexes or free PAH.
The presence or absence of antibodies to each of the PAH-DNA adducts was compared to the gender, age, and to the current and past smoking status of the individual serum almost all ofthe persons (both females and males) contributing sera to these studies had smoked at least one time during their lives. Exposure through passive smoking was not controlled in this study either. We therefore cannot preclude the possibility that the primary antibody responses were produced against DNA adducts formed from PAH contained in tobacco smoke. Analysis of the antibody data using total cigarette comsumption, as estimated by pack years, using a pooled sample of current and past smokers, revealed a difference in the responses that was associated with the gender of the volunteers. Females with antibodies in their sera to PAH-DNA adducts were readily identified in all of the test groupings, regardless of their total cigarette consumption. The highest proportions of antibody positive donors was in the group with the lowest total cigarette consumption levels, 1-20 pack years. Male serum donors with antibodies to any ofthe adducts were not found in this lowest pack years group (Table II) . The percentage of antibody positive females remained similar as pack year estimates increased. However, the proportion of antibody positive males increased as pack years estimates increased.
We analyzed these data further by ranking the serum donors with positive smoking histories according to their pack years estimates and genders. These groups were then divided into terciles of similar sizes based on pack years estimates. The terciles distribution for the males was as follows: (a) 1-25 pack years, median of 13 pack years, 12 individuals; (b) 26 The data were examined across terciles using the extended Mantel-Haenszel test. We found that the increases in the percentages of antibody positive males was associated with increases in pack years estimates but this trend did not quite reach a significant level (P < 0.072). There was no association between the pack years estimates and the presence of antibodies to PAH-DNA adducts for the female group. These data suggested a gender-exposure interaction in the male volunteers and a smoking status-exposure interaction as well since former smokers tended to have a lower cumulative exposure than the current smokers.
Antibody titers were estimated for all of the test sera as quantitative measurements ofthe PAH-DNA specific antibodies. The titers for antibodies to each ofthe three types of PAH-DNA adducts are listed in Table III . In general, antibody titers were low with most values in the 25-125 range. There was no correlation of antibody titer with gender, smoking history, or the age of the volunteer.
Discussion
We have reported that the serum from coke oven workers frequently contain antibodies against PAH-DNA adducts, the testing was done using BPDE-DNA (15) . These workers are exposed routinely to very high levels of PAH in their occupational environment and therefore, the presence of these antibodies is thought to reflect PAH exposure levels. The results of the present study demonstrate that persons with levels of exposure to PAH typical of urban environments also produce antibodies to BPDE-DNA as well as to the DNA adducts ofthe related PAH, BADE, and ChDE (Fig. 1) . These data support our initial observation that persons are capable of producing an immune response against certain PAH-DNA adducts. These current data further our initial observation in that they demonstrate that typical environmental levels of PAH exposure can serve to induce an immune response and that antibodies are produced against more than a single type of PAH-DNA adduct (Fig. 2) .
The specificity of the serum antibodies for PAH-DNA adducts was readily demonstrated using the direct binding ELISA and the antigen competition ELISA. The results of these assays showed that the antibodies reacted against PAH adducts on DNA only; BPDE-globin and free BP, BA and chrysene failed to compete with the PAH-DNA for antibody binding. This observation has lead us to propose that the PAH-DNA adducts were the antigens against which the antibody responses were produced. The presence ofthese antibodies must therefore reflect both exposure to the specific PAH and metabolic activation of the PAH to their electrophilic forms (9) (10) (11) (12) (13) . Antibodies specific for a particular PAH-DNA adduct and antibodies that recognized more than a single PAH-DNA adduct were also identified. Of particular interest were those sera with antibodies that bound to both ChDE-DNA and BPDE-DNA. In the example shown (Fig. 4 A) , the binding ofantibodies in serum F8066 to solid-phase BPDE-DNA could be inhibited by fluid-phase BPDE-DNA but not by fluid-phase ChDE-DNA. This was in contrast to what was expected since high levels of antibody binding to ChDE-DNA could be observed using the direct antibody binding ELISA (Fig. 2 B) . Fluidphase BPDE-DNA could also inhibit the binding of serum F8066 antibodies to solid-phase ChDE-DNA, to a greater extent than fluid-phase ChDE-DNA could be used to inhibit antibody binding to solid-phase ChDE-DNA (Fig. 4 B) . The reverse situation was not true, fluid phase ChDE-DNA could not inhibit antibody binding to solid phase BPDE-DNA. These data clearly demonstrate an antibody binding preference in serum F8066 for the BPDE-DNA over the ChDE-DNA; the major portion of total antibody binding was to BPDE-DNA when both of the PAH-DNA were present in the same ELISA test well. We have therefore considered the antibodies in this serum as being directed against BPDE-DNA and the binding to ChDE-DNA was considered to be a serological cross-reaction. Similar cross-reactivity between ChDE-DNA and BADE-DNA was observed using this serum (Fig. 4 B) . However, cross-reactivity between BADE-DNA and BPDE-DNA was not observed using serum F8066 (Fig. 4 A) , serum F7435 (Fig. 4 C) , or five other sera with complex antibody binding profiles and several very specific sera (data not shown). These data have lead us to hypothesize that antibodies are more readily produced against the BPDE-DNA and BADE-DNA adducts and further that the binding against the ChDE-DNA adducts is due primarily to serological cross-reactivity.
The combination of direct antibody binding ELISA and antigen competition ELISA proved to be very valuable for determining antibody specificity, as described in the preceding paragraph. However, we felt it was also important to document the binding of human antibodies to PAH-DNA adducts using a fluid-phase assay system since the attachment of antigens to a solid phase may alter or destroy certain epitopes. Our data demonstrated that the antibodies to PAH-DNA adducts can bind to both fluid-phase and solid-phase BPDE-DNA and BADE-DNA. Both of these PAH-DNA adduct preparations were recognized and bound by antibodies in the fluid phase and thus they were able to inhibit the antibody binding to the solid-phase adducts by 68-88%. In both cases we were not able to inhibit antibody binding to the solid-phase antigen totally by fluid-phase PAH adducted DNA when the antigens were present in both phases in the same quantities (400 ng/ml; 20 ng/well). We believe this represents a condition ofequilibrium binding of the antibodies whereby the antibodies can dissociate from either the fluid-or solid-phase antigen and then bind to the other antigen phase. Complete inhibition of antibody binding to solid phase PAH-DNA by fluid-phase adducts would therefore not be predicted as was the situation in this study. However, this was not the case when the ChDE-DNA was involved and BPDE-DNA were used as competing antigens since most ofthe test serum antibodies appeared to recognize BPDE-DNA preferrentially. Further evaluation of these observations will require that equilibrium binding experiments be done. These experiments represent the topic of future studies.
Although antibodies to PAH-DNA adducts were produced at detectable levels by many ofthe volunteers in the test population (43%), this did not represent the majority of our test group. The reasons .for this are unknown but may be associated with different levels of PAH-exposure, a variable that could not be accurately assessed in this study. Data obtained previously (15) using coke oven workers as serum donors were very similar with respect to B[a]P; only 28% of the persons sampled had antibodies to BPDE-DNA compared to 33% found in this study. Coke oven workers are exposed to much higher levels of PAH than the average individual (8) and yet the percentage of antibody responders did not increase. However, the amounts of BPDE-DNA specific antibodies in those sera appeared to be substantially higher as measured by both the antibody titers and the absorbance levels obtained using the ELISA. Evaluation ofantibody titers to BPDE-DNA in the sera used for the current study demonstrated that most ofthese antibodies were present at very low levels. Only 12% of the positive samples (4/33) had antibody titers greater than 125 and a total of 58% ofthe positive samples (19/33) had antibody titers of only 25. This is in contrast to the data obtained using serum samples from coke oven workers where 73% (8/11) of the antibody positive samples had titers of 625 or greater, whereas only 27% had the lower titers of 25 and 125 (15) . These observed variations in antibody titers suggest to us that the amounts of antibody that are produced, but not the presence or absence, are correlated positively with levels of PAH exposure.
Biological variables such as human genetic differences may be involved in the control of immune responses generated against epitopes on environmental carcinogens and/or the DNA adducts. Interindividual variations have been documented with respect to human antibody responses following vaccination or infection by measles virus (25) , and infection by Plasmodium falciparum (26) . The ability of humans to respond to these and other antigens such as insulin from different species is under the control ofthe major histocompatibility system (HLA) (25) (26) (27) . Similar genetic control mechanisms may be involved in the production ofantibodies to epitopes on PAH-DNA adducts.
Similar genetic restraints may have been involved with the observation that antibody responses were usually broadly reactive, with antibodies being produced against multiple different forms of PAH-DNA adducts, or else totally negative.
We feel it likely that only certain individuals are genetically capable of mounting an immune response to the PAH-DNA adducts but that this ability may not be specific to any particular PAH-DNA adduct. Antibody responses against many different forms of PAH-DNA adducts or a complete lack of any PAH-DNA adduct specific antibody responses would be expected if our hypothesis is valid. The genetic control of antibody responses in both the mouse and man against simple, chemically defined antigens and chemical moieties on macromolecular proteins hapten-carrier complexes, is known to be mediated through the genes and products of the major histocompatibility system, particularly the class II genes and antigens (28, 29). The chemical nature of the PAH-DNA adducts used in this study is very similar to the classical organization of chemical haptens on macromolecular carriers. We therefore believe it likely that the MHS may exert immune response gene control over the antibody responses to PAH-DNA adducts. Further experimentation using genetically defined animals or persons of known HLA types and including the measurement of other immune parameters will be required to address this issue.
Differences between the ability of individuals to metabolize PAH to form adducts with DNA and to remove or repair these adducts are known to exist (30, 31) . Levels of metabolic oxidation ofother xenobiotics have been shown to vary and to be partially under genetic control (32, 33) . Furthermore, epidemiological data suggest that the higher rates of metabolic oxidation of at least one xenobiotic, debrisoquine, are associated with susceptibility to lung cancer (34) . The ability or lack of ability of a person to metabolize PAH to form PAH-DNA adducts and to produce antibodies against these PAH-DNA adducts may be associated. We are currently evaluating serum samples from individuals for the presence of antibodies to PAH-DNA adducts and concurrently determining oxidation phenotypes using debrisoquine. If such a correlation does exist then metabolic oxidation phenotypes and the presence of antibodies to PAH-DNA adducts could be used either together or separately as markers to assess individual cancer risk.
We did not identify any simple significant associations between smoking status and the presence of antibodies to PAH-DNA adducts. However, we did find that the production of antibodies to PAH-DNA adducts was different in males and females. The failure to observe definitive correlations in our study may not be so unexpected since exposure to PAH is not limited to the use of tobacco products. Additionally, tobacco usage may be partially immunosuppressive so that high antibody production will be limited by active cigarette smoking. The relationship between antibody production and cigarette smoking will need to be evaluated using persons with well documented smoking histories and including information about the duration of smoking cessation for past smokers. Further evaluation of epidemiological data involving the dietary habits of volunteers may also allow for a more detailed assessment of these types of data. In depth studies to address these points are in progress or are being organized.
The time of initial antigenic stimulation which lead to the production of PAH-DNA adduct specific antibodies could not be determined in this study. When one considers the potential longevity of immunological memory that can be recalled upon reexposure to antigen then it seems plausible that the initial immune stimulus could have occurred many years previously. In fact, we propose that antibodies to chemical carcinogen-DNA adducts are indicators of current or past exposure to certain specific carcinogens and that these antibodies may be useful as biological tools in epidemiological studies particularly as they relate to cancer. Studies to evaluate the occurrence of antibodies to PAH-DNA adducts in cancer patients are currently in progress.
